Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. Outside of Eledon, Dr. Gros is the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products with over 500 employees. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.
Transforming Lives. One Organ at a Time.